IMMUNOGENICITY OUTCOMES OF A RANDOMIZED, MULTICENTER, INTERVENTIONAL, FIRST-IN-HUMAN, PHASE 1/2A STUDY OF VAC52416 (EXPEC10V), A VACCINE CANDIDATE FOR THE PREVENTION OF INVASIVE ESCHERICHIA COLI DISEASE
International Journal of Infectious Diseases, vol. 130, pp. S114
Abstract
stantiated events were greatest in the WHO African Region (1684 events, 31%) and the WHO Region of the Americas (1312 events, 24%) and, similarly, by year, the burden was highest in those WHO regions.Globally, over time, two-thirds (3536, 65%) of substantiated events were initially reported by WHO and infectious diseases (4298, 79%) were the predominant cause of public health events.However, other causes, including animal origin or zoonoses were also important and disaster related events were on the rise in recent years, particularly in some WHO Regions.Conclusion: WHO has a robust system for global disease detection but health threats are continuously evolving.The impact of climate change and zoonoses is becoming more pronounced, emphasizing the importance of a One Health approach for disease detection.
Authors 10
-
Johnson County Clin-Trials (United States)
Affiliation as printed
Johnson County Clin-Trials , Clinical Trials , Lenexa , AL , United States of America
Johnson County Clin-Trials, Clinical Trials, Lenexa, AL, United States of America
-
Affiliation as printed
Janssen Vaccines , Cilag GmbH International , Bern , Switzerland
Janssen Vaccines, Cilag GmbH International, Bern, Switzerland
-
Affiliation as printed
Janssen Research & Development , Janssen Pharmaceutica , Infectious Diseases & Vaccines , Beerse , Belgium
Janssen Research & Development, Janssen Pharmaceutica, Infectious Diseases & Vaccines, Beerse, Belgium
-
Affiliation as printed
Janssen Research & Development , Janssen Pharmaceutica , Infectious Diseases & Vaccines , Beerse , Belgium
Janssen Research & Development, Janssen Pharmaceutica, Infectious Diseases & Vaccines, Beerse, Belgium
-
Janssen Research & Development (United States)
Affiliation as printed
Janssen Research & Development , US Stats & Dec Scien , Raritan , NJ , United States of America
Janssen Research & Development, US Stats & Dec Scien, Raritan, NJ, United States of America
-
Janssen Research & Development (United States)
Affiliation as printed
Janssen Research & Development , Bacterial Vaccine US , Raritan , NJ , United States of America
Janssen Research & Development, Bacterial Vaccine US, Raritan, NJ, United States of America
-
Affiliation as printed
Janssen Vaccines & Prevention B.V. , Leiden , Bacterial Vaccines Discovery and Early Development , Leiden , Netherlands
Janssen Vaccines & Prevention B.V., Leiden, Bacterial Vaccines Discovery and Early Development, Leiden, Netherlands
-
Affiliation as printed
Janssen Vaccines & Prevention B.V. , Leiden , Bacterial Vaccines Discovery and Early Development , Leiden , Netherlands
Janssen Vaccines & Prevention B.V., Leiden, Bacterial Vaccines Discovery and Early Development, Leiden, Netherlands
-
Janssen Research & Development (United States)
Affiliation as printed
Janssen Research & Development (at the time of the analysis) , Bacterial Vaccine US , Raritan , NJ , United States of America
Janssen Research & Development (at the time of the analysis), Bacterial Vaccine US, Raritan, NJ, United States of America
-
Affiliation as printed
Janssen Research & Development , Janssen Pharmaceutica , Infectious Diseases & Vaccines , Beerse , Belgium
Janssen Research & Development, Janssen Pharmaceutica, Infectious Diseases & Vaccines, Beerse, Belgium
Cited by 2 stored of 2
2 results
No patents citing this paper on Lens.org (checked 2026-10-11).